Impact of Anti-amyloid-β Monoclonal Antibodies on the Pathology and Clinical Profile of Alzheimer’s Disease: A Focus on Aducanumab and Lecanemab

Aducanumab Use in Symptomatic Alzheimer Disease Evidence in Focus: Report of the AAN Guidelines Subcommittee

(2022) Gregory S Day et al.   NEUROLOGY

ENGAGE and EMERGE: Truth and consequences?

(2021) Lewis H. Kuller et al.   Alzheimers & Dementia

A comparative study of the effects of Aducanumab and scanning ultrasound on amyloid plaques and behavior in the APP23 mouse model of Alzheimer disease

(2021) Gerhard Leinenga et al.   Alzheimers Research & Therapy

A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody

(2021) Chad J. Swanson et al.   Alzheimers Research & Therapy

Effects of monoclonal antibodies against amyloid-β on clinical and biomarker outcomes and adverse event risks: A systematic review and meta-analysis of phase III RCTs in Alzheimer’s disease

(2021) Konstantinos I. Avgerinos et al.   AGEING RESEARCH REVIEWS

Safety, Tolerability, and Pharmacokinetics of High‐Volume Subcutaneous Crenezumab, With and Without Recombinant Human Hyaluronidase in Healthy Volunteers

(2021) Michael J. Dolton et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Critical Appraisal of Amyloid Lowering Agents in AD

(2021) Boris Decourt et al.   Current Neurology and Neuroscience Reports

Aducanumab: First Approval

(2021) Sohita Dhillon   DRUGS

Alzheimer's and Aducanumab: Unjust Profits and False Hopes

(2021) Leonard M. Fleck   HASTINGS CENTER REPORT

Elevated soluble amyloid beta protofibrils in Down syndrome and Alzheimer's disease

(2021) Malin Johannesson et al.   MOLECULAR AND CELLULAR NEUROSCIENCE

A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer’s disease

(2021) Stephen Salloway et al.   NATURE MEDICINE

Aducanumab for Alzheimer’s disease: A regulatory perspective

(2021) Robert Nisticò et al.   PHARMACOLOGICAL RESEARCH

Predicted Lifetime Health Outcomes for Aducanumab in Patients with Early Alzheimer’s Disease

(2021) William L. Herring et al.   Neurology and Therapy

Passive antiamyloid immunotherapy for Alzheimerʼs disease

(2020) Júlia C. Loureiro et al.   CURRENT OPINION IN PSYCHIATRY

Progression of Alzheimer's disease and effect of scFv‐h3D6 immunotherapy in the 3xTg‐AD mouse model: An in vivo longitudinal study using Magnetic Resonance Imaging and Spectroscopy

(2020) J. Güell‐Bosch et al.   NMR IN BIOMEDICINE

Pharmacokinetics and pharmacodynamic effect of crenezumab on plasma and cerebrospinal fluid beta-amyloid in patients with mild-to-moderate Alzheimer’s disease

(2020) Kenta Yoshida et al.   Alzheimers Research & Therapy

Safety, Tolerability, and Pharmacokinetics of Crenezumab in Patients with Mild-to-Moderate Alzheimer’s Disease Treated with Escalating Doses for up to 133 Weeks

(2020) Heather Guthrie et al.   JOURNAL OF ALZHEIMERS DISEASE

N‐terminal heterogeneity of parenchymal and vascular amyloid‐β deposits in Alzheimer’s disease

(2020) S. Zampar et al.   NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY

Aducanumab, gantenerumab, BAN2401, and ALZ-801—the first wave of amyloid-targeting drugs for Alzheimer’s disease with potential for near term approval

(2020) Martin Tolar et al.   Alzheimers Research & Therapy

Kinetic fingerprints differentiate the mechanisms of action of anti-Aβ antibodies

(2020) Sara Linse et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

Target Dysbiosis of Gut Microbes as a Future Therapeutic Manipulation in Alzheimer’s Disease

(2020) Feiqi Zhu et al.   Frontiers in Aging Neuroscience

Solanezumab in‐depth outcomes

(2020) Martin R. Farlow et al.   Alzheimers & Dementia

Emerge and Engage topline results: Phase 3 studies of aducanumab in early Alzheimer’s disease

(2020) Samantha Budd Haeberlein et al.   Alzheimers & Dementia

Anti-Neuroinflammatory Potential of Polyphenols by Inhibiting NF-κB to Halt Alzheimer's Disease

(2020) Md. Sahab Uddin et al.   CURRENT PHARMACEUTICAL DESIGN

Lessons Learnt from the Second Generation of Anti-Amyloid Monoclonal Antibodies Clinical Trials

(2020) Angela Tian Hui Kwan et al.   DEMENTIA AND GERIATRIC COGNITIVE DISORDERS

Anti-Aβ Antibody Aducanumab Regulates the Proteome of Senile Plaques and Closely Surrounding Tissue in a Transgenic Mouse Model of Alzheimer’s Disease

(2020) Joakim Bastrup et al.   JOURNAL OF ALZHEIMERS DISEASE

Can Anti–β-amyloid Monoclonal Antibodies Work in Autosomal Dominant Alzheimer Disease?

(2020) Bruno P. Imbimbo et al.   Neurology-Genetics

A critical appraisal of amyloid-β-targeting therapies for Alzheimer disease

(2019) Francesco Panza et al.   Nature Reviews Neurology

Pyroglutamation of amyloid-βx-42 (Aβx-42) followed by Aβ1-40 deposition underlies plaque polymorphism in progressing Alzheimer’s disease pathology

(2019) Wojciech Michno et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Antibiotics, gut microbiota, and Alzheimer’s disease

(2019) Francesco Angelucci et al.   Journal of Neuroinflammation

Treatment with scFv-h3D6 Prevented Neuronal Loss and Improved Spatial Memory in Young 3xTg-AD Mice by Reducing the Intracellular Amyloid-β Burden

(2019) Gisela Esquerda-Canals et al.   JOURNAL OF ALZHEIMERS DISEASE

Pharmacokinetic parameters and mechanism of action of an efficient anti-Aβ single chain antibody fragment

(2019) Gisela Esquerda-Canals et al.   PLoS One

The path forward in Alzheimer's disease therapeutics: Reevaluating the amyloid cascade hypothesis

(2019) Martin Tolar et al.   Alzheimers & Dementia

The role of innate immune responses and neuroinflammation in amyloid accumulation and progression of Alzheimer's disease

(2019) Alessandra Webers et al.   IMMUNOLOGY AND CELL BIOLOGY

Passive Immunotherapies Targeting Amyloid Beta and Tau Oligomers in Alzheimer’s Disease

(2019) Crystal M. Vander Zanden et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

A resurrection of aducanumab for Alzheimer's disease

(2019) Lon Schneider   LANCET NEUROLOGY

Gantenerumab reduces amyloid-β plaques in patients with prodromal to moderate Alzheimer’s disease: a PET substudy interim analysis

(2019) Gregory Klein et al.   Alzheimers Research & Therapy

High complement levels in astrocyte-derived exosomes of Alzheimer disease

(2018) Edward J. Goetzl et al.   ANNALS OF NEUROLOGY

Anti-Amyloid-β Monoclonal Antibodies for Alzheimer’s Disease: Pitfalls and Promise

(2018) Christopher H. van Dyck   BIOLOGICAL PSYCHIATRY

Relationship between CNS and immunology, in relation to psychology

(2018) Ghulam Md Ashraf et al.   CURRENT DRUG METABOLISM

ABBY

(2018) Jeffrey L. Cummings et al.   NEUROLOGY

Trial of Solanezumab for Mild Dementia Due to Alzheimer’s Disease

(2018) Lawrence S. Honig et al.   NEW ENGLAND JOURNAL OF MEDICINE

Structural and kinetic basis for the selectivity of aducanumab for aggregated forms of amyloid-β

(2018) Joseph W. Arndt et al.   Scientific Reports

Gantenerumab: A Novel Human Anti-Aβ Antibody Demonstrates Sustained Cerebral Amyloid-β Binding and Elicits Cell-Mediated Removal of Human Amyloid-β

(2018) Bernd Bohrmann et al.   JOURNAL OF ALZHEIMERS DISEASE

The Murine Version of BAN2401 (mAb158) Selectively Reduces Amyloid-β Protofibrils in Brain and Cerebrospinal Fluid of tg-ArcSwe Mice

(2018) Stina Tucker et al.   JOURNAL OF ALZHEIMERS DISEASE

Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer’s disease (BLAZE)

(2018) Stephen Salloway et al.   Alzheimers Research & Therapy

A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease

(2017) Susanne Ostrowitzki et al.   Alzheimers Research & Therapy

ADCOMS: a composite clinical outcome for prodromal Alzheimer's disease trials

(2016) Jinping Wang et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Immunotherapy with Aducanumab Restores Calcium Homeostasis in Tg2576 Mice

(2016) Ksenia V. Kastanenka et al.   JOURNAL OF NEUROSCIENCE

The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease

(2016) Jeff Sevigny et al.   NATURE

Bapineuzumab for mild to moderate Alzheimer’s disease in two global, randomized, phase 3 trials

(2016) Rik Vandenberghe et al.   Alzheimers Research & Therapy

Safety and tolerability of BAN2401 - a clinical study in Alzheimer’s disease with a protofibril selective Aβ antibody

(2016) Veronika Logovinsky et al.   Alzheimers Research & Therapy

Structure of Crenezumab Complex with Aβ Shows Loss of β-Hairpin

(2016) Mark Ultsch et al.   Scientific Reports

Alzheimer's disease

(2015) Colin L. Masters et al.   Nature Reviews Disease Primers

Cell-to-cell transmission of pathogenic proteins in neurodegenerative diseases

(2014) Jing L Guo et al.   NATURE MEDICINE

Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease

(2014) Rachelle S. Doody et al.   NEW ENGLAND JOURNAL OF MEDICINE

Amyloid-β and Tau

(2014) George S. Bloom   JAMA Neurology

Molecular Structure of β-Amyloid Fibrils in Alzheimer’s Disease Brain Tissue

(2013) Jun-Xia Lu et al.   CELL

Innate Immunity in Alzheimer’s Disease: A Complex Affair

(2013) Marie-Victoire Guillot-Sestier et al.   CNS & Neurological Disorders-Drug Targets

N-Methyl D-Aspartate (NMDA) Receptor Antagonists and Memantine Treatment for Alzheimer’s Disease, Vascular Dementia and Parkinson’s Disease

(2013) David Olivares et al.   Current Alzheimer Research

Molecular drivers and cortical spread of lateral entorhinal cortex dysfunction in preclinical Alzheimer's disease

(2013) Usman A Khan et al.   NATURE NEUROSCIENCE

Biomarker Modeling of Alzheimer’s Disease

(2013) Clifford R. Jack et al.   NEURON

Profile of gantenerumab and its potential in the treatment of Alzheimer's disease

(2013) Robert Nisticò et al.   Drug Design Development and Therapy

Neuropathological Alterations in Alzheimer Disease

(2013) A. Serrano-Pozo et al.   Cold Spring Harbor Perspectives in Medicine

Safety and biomarker effects of solanezumab in patients with Alzheimer’s disease

(2012) Martin Farlow et al.   Alzheimers & Dementia

Epidemiological of and risk factors for Alzheimer's disease: A review

(2012) Jana Povova et al.   BIOMEDICAL PAPERS-OLOMOUC

Solanezumab for the treatment of mild-to-moderate Alzheimer’s disease

(2012) Bruno P Imbimbo et al.   Expert Review of Clinical Immunology

Immunotherapy for Alzheimer’s disease: from anti-β-amyloid to tau-based immunization strategies

(2012) Francesco Panza et al.   Immunotherapy

Florbetapir PET analysis of amyloid-β deposition in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: a cross-sectional study

(2012) Adam S Fleisher et al.   LANCET NEUROLOGY

Alzheimer’s drugs take a new tack

(2012) Ewen Callaway   NATURE

Indicators of amyloid burden in a population-based study of cognitively normal elderly

(2012) M. M. Mielke et al.   NEUROLOGY

Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease

(2012) Randall J. Bateman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Stopping Alzheimer's Before It Starts

(2012) G. Miller   SCIENCE

Amyloid-like Aggregates Sequester Numerous Metastable Proteins with Essential Cellular Functions

(2011) Heidi Olzscha et al.   CELL

Sink Hypothesis and Therapeutic Strategies for Attenuating Aβ Levels

(2011) Yan Zhang et al.   NEUROSCIENTIST

Cerebrospinal fluid and plasma biomarkers in Alzheimer disease

(2010) Kaj Blennow et al.   Nature Reviews Neurology